Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 9.01 · 8-K

ABBVIE INC.

ABBVNYSEEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.…

Filed Jul 6, 2026Accepted Jul 6, 2026, 4:12 PM EDTCIK 1551152Accession 0001551152-26-000021
Share

Company context

AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline - spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Current securities

Recent company filings

  1. 144 filingNov 16, 2026
  2. 10-Q filingNov 3, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 2, 2026
  4. Results of Operations and Financial ConditionOct 30, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 15, 2026

Registered securities in this filing

ABBVIE INC. · 8-K · Filed 2026-07-06

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.01 Par Value

Symbol
ABBV
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

Common Stock, $0.01 Par Value

Symbol
ABBV
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

0.750% Senior Notes due 2027

Symbol
ABBV27
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-4

Dimensions: us-gaap:StatementClassOfStockAxis

2.125% Senior Notes due 2028

Symbol
ABBV28
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-5

Dimensions: us-gaap:StatementClassOfStockAxis

2.625% Senior Notes due 2028

Symbol
ABBV28B
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-6

Dimensions: us-gaap:StatementClassOfStockAxis

2.125% Senior Notes due 2029

Symbol
ABBV29
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-7

Dimensions: us-gaap:StatementClassOfStockAxis

1.250% Senior Notes due 2031

Symbol
ABBV31
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-8

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000155115226000021 · 7 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2026 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates. While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2026 previously announced on April 29, 2026 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2026. AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 2026 acquired IPR&D and milestones expense, is $13.91 - $14.11. AbbVie’s second-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 2026 acquired IPR&D and milestones expense, is $3.57 - $3.61. Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2026 including the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2026. The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Forward-Looking Statements Some statements in this Current Report on Form 8-K are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Filed exhibits (1)
EX-99.1 (by filename) abbv-20260630nonxgaapxex991.htm

EX-99.1 2 abbv-20260630nonxgaapxex991.htm EX-99.1 Document AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended June 30, 2026 Full-Year Ended December 31, 2026 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Acquired IPR&D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR&D and Milestones Expense Adjusted Diluted EPS Range Low High …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.